Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the enzyme that is rate limiting in the synthesis of glucosamine and hexosamines. Glucosamine has been proposed to contribute to the glucotoxicity of diabetes. Evidence that the gene encoding GFAT is transcriptionally regulated prompted us to clone and characterize its promoter. The position of the mouse GFAT promoter relative to the translational start site was located by primer extension and found to be 149 bp upstream of the translational start site. A 1.9 kb SacI fragment of the GFAT gene was found to contain the promoter and 88 bp of sequence downstream of the transcriptional start site. This promoter segment could drive expression of a luciferase reporter gene, could confer correct transcriptional initiation to the reporter and could confer the EGF-responsiveness previously observed in the native gene. The mouse GFAT promoter lacks a canonical TATA box and has several GC boxes within a highly GC-rich region. Deletional analysis of the promoter indicated that a proximal element extending to -120 relative to the transcriptional start site could confer reporter expression at a level of 57% of the 1.9 kb construct. Detailed analysis of this proximal region by DNase I footprinting, electrophoretic mobility shift assays and site-directed mutagenesis indicated that Sp1 binds to three elements in this proximal promoter segment and plays a vital role in regulation of transcription from this gene.
INTRODUCTION
Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the rate limiting enzyme in the hexosamine biosynthetic pathway (1) . This enzyme diverts 2-5% of the fructose-6-phosphate derived from glucose to glucosamine-6-phosphate, using glutamine as the nitrogen donor (2) . Subsequently, glucosamine-6-phosphate is metabolized to uridine diphosphate N-acetylglucosamine (UDPGlcNAc), which serves as a substrate for protein glycosylation. Recent studies have shown that the hexosamine biosynthetic pathway regulates a diverse set of cellular events, including glucose-induced insulin desensitization in adipocytes (3), glycogen synthase activity (4), pyruvate kinase activity (5) and glucose-induced growth factor expression in vascular smooth muscle cells (6) (7) (8) . These studies have shown that glucosamine, the product of GFAT activity, can mimic the effects of glucose. In some of these studies (7, 8) it has also been shown that the metabolism of glucose to glucosamine through GFAT is necessary for the effect of glucose on the respective metabolic function. Thus, it appears that it is the intracellular concentration of glucosamine, or one of its products, that mediates these metabolic changes.
The intracellular concentration of glucosamine is likely to be tightly regulated. One point of regulation of glucosamine synthesis is at the level of GFAT activity itself. This enzyme is negatively regulated in eukaryotes by its downstream product, UDP-GlcNAc, perhaps through an allosteric mechanism (9, 10) . However, the mass amount of this enzyme within the cell also appears to affect the intracellular glucosamine content. Recently, we have shown that the intracellular content of GlcNAc covalently bound to protein by O-linkage (O-GlcNAc) is an indirect measure of GFAT activity (7, 8) . This covalent modification can be measured with a monoclonal antibody, RL-2. It was observed that pharmacological blockage of GFAT activity or an antisense block of GFAT expression resulted in a decrease in the intracellular content of O-GlcNAc-modified proteins (7, 8) . In another study, overexpression of GFAT under the control of a heterologous promoter in cultured cells resulted in increased intracellular glucosamine (11) . The endogenous GFAT promoter also appears to regulate expression of this enzyme. In yeast, GFAT gene transcription can be regulated by α-pheromone (12) , and in human cells, GFAT gene transcription can be regulated by EGF, glucose and glucosamine (13) . This regulation of the GFAT promoter could potentially result in changes in glucosamine synthesis with subsequent consequences on protein glycosylation and cellular metabolism. These studies were therefore designed to molecularly clone and identify the mouse GFAT promoter and perform an initial characterization of this promoter. We found that the GFAT promoter has no TATA box, typical of most genes encoding 'housekeeping' enzymes, and that its basal transcription is mainly regulated by the transcription factor Sp1. The availability of this promoter will allow more detailed analysis of transcriptional regulation of the GFAT gene.
MATERIALS AND METHODS

Isolation of genomic DNA clones containing the GFAT promoter region
A once amplified 129SV mouse genomic library in λFixII (Stratagene, La Jolla, CA) was used to isolate the clones containing the 5′-region of the GFAT gene. Plaque lifts of 1 × 10 6 recombinants were hybridized with a 32 P-labeled 356 bp fragment of the mouse GFAT cDNA spanning from the ATG translation initiation codon to the internal EcoRI site (14) . After several low stringency washes, membranes were washed in 0.2× SSC, 1.0% SDS at 60_C for 60 min. Individual plaques were identified by autoradiography and purified to homogeneity through subsequent rounds of screening.
5′ Rapid amplification of cDNA ends (5′-RACE)
5′-RACE of the GFAT transcripts was performed using the Gibco-BRL 5′-RACE kit (Grand Island, NY). Briefly, first strand cDNA was synthesized using 3 µg poly(A + ) RNA isolated from NIH 3T3 cells and a GFAT gene-specific primer corresponding to nucleotides +91 to +48 relative to the ATG translation initiation codon. After incubation with 8 U SuperScript reverse transcriptase for 30 min at 42_C, the RNA template was degraded with RNase H and the cDNA was purified using the GlassMax DNA Isolation Spin Cartridge System. The 3′-ends of the cDNA were tailed using 10 U terminal deoxynucleotide transferase and 2 mM dCTP. The cDNA pool was then amplified by PCR using the Gibco-BRL poly(dGTP) anchor primer and a nested GFAT gene-specific primer corresponding to cDNA nucleotides +54 to +30 relative to the ATG translation initiation codon. The primer contained an EcoRI restriction site. PCR amplification was carried out for 40 cycles with an anealing temperature of 50_C and this gave rise to a single band of ∼250 bp. The product was digested with EcoRI and SalI, ligated into correspondingly cut pT7T3 (Pharmacia, Piscataway, NJ) and independent clones were sequenced on both strands. The GFAT promoter (-470/+88) was placed upstream of the firefly luciferase cDNA (pGL-2 Basic; Promega, Madison, WI) and this plasmid was subsequently transfected into NIH 3T3 cells. 5′-RACE of the luciferase transcript as directed by the GFAT promoter was performed to determine the conferred transcriptional start site. At 40 h post transfection, poly(A + ) RNA was isolated to serve as a template for primer extension using nested luciferase gene-specific primers as follows: cDNA synthesis primer, 5′-AATGGCGCCGGGCCTTTCTTTATGTTTTTGGCGTCTT-CCATT-3′; PCR primer, 5′-CCATTTTACCAACAGTACCGGA-ATG-3′. After PCR amplification, the unique product was digested with XhoI and SalI, cloned into pT7T3 and independent clones were sequenced on both strands.
DNA sequencing
DNA sequencing was performed by the dideoxy chain termination method (15) employing the Sequenase Version 2.0 sequencing kit (USB, Cleveland, OH). The SacI-SacI 1.9 kb genomic DNA fragment was cloned into pT7T3 and sequenced using a series of overlapping nested primers. Computer sequence analysis was done with the GCG Version 7.2 Fragment Assembly System (FAS) and overlap was identified between the genomic sequence and the 5′-RACE products.
Construction of GFAT-luciferase plasmids
The SacI-SacI 1.9 kb genomic DNA fragment (corresponding to -1822/+88 relative to the transcription initiation site) was cloned into pGL-2 Basic. The -470/+88 construct was generated by cutting the vector with KpnI and closing with ligase. The remaining deletant constructs were prepared by PCR amplification using the following oligonucleotides: 5′-CGGGGTACCTACAGCTTTT-CTCTCTGTC-3′ (for -275/+88); 5′-CATGGTACCCGCAGCT-CTGCGTCTG-3′ (for -120/+88); 5′-CATGGTACCCAATGG-GAGAGCCG-3′ (for -55/+88); with the bottom strand primer being the luciferase PCR primer listed above. The 5′-untranslated region (UTR) variants were also generated by PCR, with the bottom strand oligonucleotides being 5′-CATGGATCCAGCGC-TCGCTTCGCTCTC-3′ (for -470/+19) and 5′-CATGGATC-CGATGTTGGTCACGGGCGAG-3′ (for -470/+149), with the top strand primer being 5′-GTGCTGGGACTACTGAC-3′. For site-directed mutagenesis, constructs were generated as previously described (16) . Briefly, the GFAT-luciferase vector (-120/+88), which contains an F1 origin, was used to generate ssDNA with R408 helper phage. Oligonucleotides bearing different restriction sites for each of the seven mutant constructs were used to prime second strand synthesis. After plasmid purification, all mutations were confirmed by both restriction digestion and sequencing.
Tissue culture and electroporation
NIH 3T3 and MDA468 cells were passed weekly in Dulbecco's modified Eagle's medium (DMEM) + 10% neonatal calf serum (NCS) supplemented with 100 µg/ml penicillin and 50 µg/ml gentamicin. For transfections, 6 × 10 6 cells were trypsinized, washed with cold phosphate-buffered saline and resuspended in DMEM + 10% NCS and 12 µg appropriate luciferase plasmid were added in addition to 8 µg pCMV-βGal reporter plasmid to normalize for transfection efficiency. Cells were electroporated at 400 (NIH 3T3) or 350 V (MDA468) and 500 µF in a Gene Pulser (BioRad, Richmond, CA) and plated at a density of 5 × 10 5 cells/well using 6-well plates (Fisher Scientific, Atlanta, GA).
Luciferase activity was measured in detergent extracts of cells in the presence of ATP and luciferin as previously described (17) using a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). Light output was integrated over a 10 s period and displayed as relative light units (RLU). Background activity was found to be <4% of all readings. The same extracts were assayed for β-galactosidase activity as previously described (18) . All β-galactosidase activities were within the linear range of the absorbance curve.
Eukaryotic expression of recombinant Sp1 and SpN proteins
The full-length human Sp1 cDNA was cloned downstream of the cDNA encoding the glutathione S-transferase (GST) protein. The GST-Sp1 sequence was then cloned into the pTM3 vector and a recombinant vaccinia virus (vGST-Sp1) was generated using selection methods previously described (19, 20) . After co-infecting BSC-40 cells with vGST-Sp1 and vTF7-3 viruses, protein extracts were prepared as described (20) . The fusion protein was affinity purified by incubating with glutathione covalently linked to Sepharose beads (Pharmacia, Piscataway, NJ). After several washes, the beads were resuspended and the Sp1 protein was released by cleaving with thrombin. The Sp1-containing supernatant was cleared of thrombin by incubation with Sepharose beads covalently linked to benzamidine (Pharmacia, Piscataway, NJ). Concentration was determined by the BioRad D c Protein Assay (Richmond, CA). SpN protein is encoded by the same cDNA but lacks the N-terminal 83 amino acids, resulting in a protein of ∼80 kDa. The SpN cDNA was cloned directly into pTM3, generating the recombinant virus vSpN. After co-infection with vTF7-3, protein extracts were prepared and SpN protein was partially purified using wheatgerm agglutinin chromatography (21) . After elution from the column, protein concentrations were determined using the BioRad D c Protein Assay (Richmond, CA).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from MDA468 cells as previously described (16, 22) . The GFAT oligonucleotide were made by annealing two complementary sequences spanning the indicated sequences in the GFAT promoter. 5′-Overlaps were provided to allow labeling with 32 P using Klenow enzyme. Approximately 20 fmol DNA were added to a nuclear extract containing 2.5 µg protein in a final volume of 25 µl 20 mM HEPES, pH 7.9, 50 mM KCl, 1 mM dithiothreitol (DTT), 10% glycerol and 1 µg poly(dI·dC). Following a 20 min incubation at room temperature, DNA-protein complexes were resolved by electrophoresis on a 5.5% non-denaturing polyacrylamide gel with 90 mM Tris-borate, 2 mM EDTA buffer. For antibody experiments, the radiolabeled probe was added subsequent to a 25 min pre-incubation of nuclear extract with antibody at 4_C. The human AP-2 and Sp1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and another human Sp1 antibody is described elsewhere (23) .
DNase I footprinting
The vector containing the GFAT promoter (-470/+88) driving firefly luciferase was linearized with HindIII and end-labeled with Klenow enzyme. After secondary digestion with KpnI, the purified labeled 450 bp fragment was incubated with proteins in a final volume of 50 µl with buffer containing 25 mM Tris, pH 8.0, 6.25 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 7.5% glycerol, 10 µg bovine serum albumin and 200 ng poly(dI·dC) for 25 min at 4_C. Varying concentrations of DNase I were added and allowed to react for 30-120 s. The reactions were stopped with EDTA, phenol/chloroform extracted and ethanol precipitated. The digested DNA was electrophoresed on a 6% acrylamide-urea DNA sequencing gel prior to autoradiography. The exact locations of the DNase I footprints were determined by comparison with sequences of known length electrophoresed concurrently.
RESULTS
Identification of transcription initiation site(s)
Although the sequence of the entire open reading frame for the mouse GFAT cDNA was previously determined (14) , the GFAT mRNA was found to be as much as 5 kb larger than the open reading frame. In order to orient the GFAT promoter relative to the coding sequence and identify the GFAT transcription start site(s), we used the 5′-RACE method to perform primer extension on the GFAT mRNA. The single 5′-RACE product of ∼200 bp was cloned and four individual clones were sequenced on both strands. The sequence was identical for all clones and each contained the 50 bp sequence 3′ of the ATG translation initiation sequence, allowing identification of these sequences as GFAT. Furthermore, all clones were found to initiate from the same guanidine nucleotide 149 bases upstream of the ATG translation initiation codon (DDBJ/EMBL/GenBank accession no. U39442).
Cloning of the 5′-flanking region of the GFAT gene
A mouse genomic library was screened using a probe derived from the 5′-end of the GFAT cDNA (14) . Four clones were isolated after screening ∼2 × 10 6 λ phage plaques. In order to identify which of these clones contained the 5′-end of the GFAT gene, phage plaques from these four clones were probed with an oligonucleotide representing a sequence from the 5′-UTR (primer 642). Two of these clones were positive when probed with this oligonucleotide. Restriction digests of DNA from the two positive clones resulted in identification of an identical 1.9 kb SacI fragment from both clones which could be hybridized to primer 642. Southern blotting of mouse genomic DNA cut with SacI and probed at high stringency with this segment of the GFAT gene revealed the same unique 1.9 kb fragment (data not shown). This 1.9 kb SacI fragment was subcloned into pT7T3 and sequenced using a series of overlapping primers (DDBJ/EMBL/ GenBank accession no. U39442). The sequence of the 3′-end of this SacI genomic fragment corresponded exactly to 88 bp of the 5′-RACE cDNA product, beginning with the transcription start site and continuing to the endogenous SacI site. To determine whether an intron was present in the segment of the gene encoding the 5′-UTR, the original λ phage genomic DNA was sequenced using primer 642. The resulting sequence corresponded exactly to the 5′-RACE product from the priming site to the ATG translation initiation sequence, thus establishing the lack of an intron in this segment of the GFAT gene.
Characterization of the GFAT promoter
The sequence immediately upstream of the transcription start site is GC rich and lacks a TATA box, a feature typical of housekeeping genes. In a transient transfection assay using a construct in which the 1.9 kb SacI-SacI fragment was placed upstream of firefly luciferase in the native orientation, reporter activity was readily detected (see below). However, placement of this gene segment in reverse orientation in this reporter plasmid resulted in a total loss of transcriptional reporter activity (data not shown). To confirm that this fragment of the GFAT gene confers proper transcriptional initiation to a heterologous reporter gene, the transcriptional start site of the luciferase reporter mRNA, whose expression was driven by this segment of the gene, was determined by 5′-RACE. Five such clones were sequenced on both strands. Relative to the +1 start site determined for the native gene, these reporter transcripts were found to initiate from -4, -3, -3, +1 and +3. This finding indicates that the 5′-flanking sequence of the GFAT gene confers a transcriptional start site either identical or very close to the start site of the native gene to a reporter gene. The small variance observed between the native and reporter start sites is consistent with the usual finding that housekeeping genes lacking a TATA box often initiate at a cluster of sites. However, it remains possible that the portion of the promoter used in the reporter plasmid is incomplete or that the Figure 1 . Deletional analysis of the GFAT promoter. GFAT 5′-promoter deletants were made as described in Materials and Methods and these truncated promoters were placed upstream of the luciferase reporter gene. After transfection into NIH 3T3 cells with the CMV-βGal plasmid, extracts were examined for luciferase and β-galactosidase activity. The construct containing the largest segment of the GFAT gene, -1822/+88, is arbitrarily assigned the value of 100% and all other values are relative to it after normalizing for β-galactosidase activity. Results are the means of two experiments, each performed in triplicate. All standard deviations were <10% of the means. RLU is relative light units.
number of 5′-RACE products that were sequenced was too small to detect this variability in the native gene.
In order to identify the proximal GFAT promoter, deletional analysis of the 5′-end of the promoter was undertaken and activity of the resulting truncated promoter was determined by transient transfection assays into the mouse fibroblast cell line NIH 3T3. The cells were co-transfected with a CMV-β-galactosidase construct to control for transfection efficiency (Fig. 1) . Deletion of sequences distal to -470 resulted in some augmentation of reporter function relative to the 1.9 kb SacI promoter fragment, while deletion of the segment between -470 and -275 resulted in no loss of promoter activity. The segment of the promoter between -275 and -120 contributed significantly to promoter function, but residual activity following deletion of this segment left a construct with 57% of the activity of the full-length promoter. Further deletion to -55 resulted in a loss of most of the promoter activity. This finding indicated that the segment of the gene between -120 and +88 contained the core promoter element. Computer analysis of the segment of the gene downstream (+1 to +88) of the transcriptional initiation site(s) predicted an RNA transcript with secondary structure. The predicted stem-loop structure has a calculated free energy of -46.1 kcal/mol and such potentially stable structures have been shown to have an impact on activity of the adjacent promoter (24) . Nevertheless, deletion of this segment of the gene had no detectable impact on reporter activity when tested in the context of the -470 promoter. This delineation of the core promoter directed our further studies on the DNA-protein interactions that control transcription from this segment of the gene.
DNase I footprint analysis of the GFAT promoter
The sequence of the core promoter was computer searched against a transcription factor database. In the region of the promoter near to the transcriptional start site were overlapping putative binding sites for Sp1 (-17 to -5) and AP-2 (-28 to -16). More distally there was an additional putative Sp1 site (-89 to 
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-83). To determine if Sp1 indeed binds to these consensus sites, DNase I footprinting analysis of this proximal portion of the GFAT promoter was performed on the top strand ( Fig. 2A) . Footprinting with purified Sp1 made using a recombinant vaccinia virus system produced three distinct footprints. Two of the footprints were localized to the consensus Sp1 binding sites at -17/-5 and -89/-83. The other site corresponded to a GC-rich sequence between -60 and -50. This latter sequence does not correspond to a consensus Sp1 binding site, but did permit binding of purified Sp1 at the concentration used in this experiment. The same segment of DNA was subjected to footprint analysis with nuclear extract from MDA468 cells. The extract from MDA468 cells proved to be of higher quality than that derived from NIH 3T3 cells. A nearly complete footprint was observed at the proximal Sp1 binding site (-17/-5), with only minor differences from the footprint created by pure Sp1. No footprinting was observed at the -60/-50 site, while a partial footprint was observed at the more distal site (-89/-83). The partial footprint at the more distal site appeared to be shifted in the 5′-direction relative to the footprint made by Sp1 and was associated with a DNase I-hypersensitive site upstream of this footprint (Fig. 2B) . No footprint was observed over the putative AP-2 binding site (-24/-17). The differences in the footprints generated by pure Sp1 versus nuclear extract probably relate both to the concentration of Sp1 in these two preparations and to the presence of other DNA binding proteins in the nuclear extract. 
Sp1 but not AP-2 interacts with the proximal GFAT promoter
To confirm the findings of DNA-protein interactions from footprinting, we used EMSA to assess the interaction of these elements on the GFAT promoter with proteins in nuclear extracts from MDA468 cells. The three regions of the promoter that were footprinted with pure Sp1 were investigated more thoroughly. Figure 3 shows EMSA using a probe spanning from -30 to +13. The major shifted bands, indicated by the arrows, were specific, since incubation with the same unlabeled oligonucleotide derived from the GFAT promoter resulted in a dose-dependent competition of binding to the probe. A consensus Sp1 oligonucleotide competed away the major upper band entirely, but was ineffective at competing the less intense lower band. A consensus AP-2 oligonucleotide was less effective than the Sp1 oligonucleotide at competing these bands. The AP-2 competitor oligonucleotide contained the sequence GGGCGG, which is at the core of the Sp1 consensus site, and this similarity might explain the weak competition observed with the AP-2 oligonucleotide. Further specificity testing also indicated that an Oct-1 binding site and a mutant Sp1 binding site could not compete for binding to the GFAT-derived oligonucleotide in the EMSA (data not shown).
To confirm that Sp1 can bind to the -30/+13 element of the GFAT promoter, partially purified recombinant Sp1 made with vaccinia virus (19) was used in the EMSA. The recombinant form of Sp1, termed SpN, lacked a 10 kDa segment from the N-terminus but still recognizes the Sp1 DNA consensus sequence (25) because the DNA binding zinc finger structure is near the C-terminus of the protein. In the EMSA, SpN characteristically 
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migrates slightly faster than native Sp1, allowing attribution of the gel shift to the recombinant form of Sp1. Gel mobility shift assays were conducted with nuclear extracts or the truncated protein as shown (Fig. 4A ) using the -30/+13 GFAT promoter probe. SpN was able to bind to the labeled oligonucleotide and the resulting complex had the predicted greater mobility than did native Sp1 in the nuclear extract. This band could also be competed by adding excess Sp1 oligonucleotide competitor. This Figure 5 . AP-2 does not bind to the proximal GFAT promoter. The ability of AP-2 to bind the -30/+13 GFAT probe was examined using EMSA in combination with an AP-2 antibody that is capable of supershifting an AP-2-DNA complex. The ability of this antibody to supershift was confirmed on a consensus AP-2 oligonucleotide (right panel). The arrowheads mark the AP-2 shift and supershift with the antibody. The AP-2 antibody had no detectable effect on either the major or minor gel shift band when tested on the GFAT probe. The minor band was made more apparent by competing away the major band with Sp1 oligonucleotide.
result confirms the observation made with footprinting, that Sp1 does bind to this segment of the GFAT promoter.
To prove that the shift observed with crude nuclear extract was due to native Sp1, an immunological approach was used in which the nuclear extract was pre-incubated with an anti-Sp1 antibody (Fig. 4B) . Treatment with pre-immune serum had no effect on the complex, while the anti-Sp1 polyclonal serum greatly reduced the dominant shift, a property expected of this Sp1 antiserum (26) . This result indicates that Sp1 is necessary for the observed major gel shift of this segment of the promoter.
The -30/+13 segment of the promoter also contains a potential AP-2 binding site. Interestingly, competition with a consensus Sp1 oligonucleotide does not completely eliminate the major gel shift and results in the retention of a minor, but specific, band. The binding of AP-2 to this segment of the promoter was therefore investigated using an antibody directed at AP-2 (27; Fig. 5 ). Using a consensus AP-2 binding site in an EMSA, this antibody was shown to supershift the AP-2-DNA complex. However, the antibody was unable to shift the complex formed on the GFAT gene. When the Sp1 band was eliminated by adding excess Sp1 oligonucleotide competitor, the remaining minor band underwent no supershift with the AP-2 antibody. Thus, AP-2 does not appear to bind the potential AP-2 binding site in this segment of the GFAT gene with sufficient affinity for detection in an EMSA.
The other two sites in the GFAT promoter that were footprinted with recombinant Sp1 were also further investigated by EMSA (Fig. 6) . A labeled oligonucleotide corresponding to the Sp1 footprint centered at -55 could form complexes with nuclear proteins, showing two principal bands. The upper band, indicated in the figure by arrow II, could be competed with a consensus Sp1 oligonucleotide and self and could be supershifted with a commercially available anti-Sp1 antibody (arrow I). Thus, this The following oligonucleotides corresponding to segments of the GFAT promoter were used for EMSA to determine whether Sp1 binds to the GFAT gene: GFAT -97/-75, top strand, 5′-CGCTCTCTGGGCGGGCGATGCC-TG-3′; GFAT -75/-48, top stand, 5′-GCGCGTGAGCGCGCGGGCGCGGC-CCAAT-3′. The labeled probes were incubated with nuclear extract that had been pre-incubated with the indicated antibodies or the indicated unlabeled oligonucleotide. The resulting DNA-protein complexes were analyzed by EMSA. The numbered arrows indicate the principal shifted bands. Band II appears to result from specific interaction between the protein and DNA.
non-consensus Sp1 binding site could be recognized by recombinant Sp1, as assessed by DNase I footprinting, and by native Sp1 in nuclear extract. We could not find evidence in the EMSA for formation of a specific DNA-protein complex with any other protein in the nuclear extract. Similarly, an oligonucleotide corresponding to the more distal Sp1 footprint, centered at -85, could form a complex with nuclear proteins with similar mobility (arrow II) and this complex was supershifted with an anti-Sp1 antibody (arrow I). These studies suggest that these two sites are preferentially recognized by Sp1, even in the presence of the mixture of transcription factors available in the unfractionated nuclear extract.
Functional studies on the Sp1 binding sites in the GFAT promoter
The functional significance of the Sp1 binding sites to the GFAT promoter was investigated by site-directed mutagenesis of the promoter. Using the -120/+88 segment of the promoter as the parent construct, seven mutations were placed along the promoter. After co-transfection of these constructs into either NIH 3T3 or MDA468 cells with CMV-β-galactosidase, the cell extracts were assayed for β-galactosidase and luciferase activities (Fig. 7) . Mutations at the three sites footprinted by purified Sp1 resulted in a significant loss of promoter activity, whereas mutations at a site not identified by footprinting (L/S -50) or at the potential AP-2 binding site (L/S -23) had no significant affect on promoter activity. Of note, a mutation at the major transcriptional initiation site also had no effect on transcription, suggesting that this region 
The proximal GFAT promoter confers a response to epidermal growth factor (EGF)
Prior studies have shown that in MDA468 cells EGF induces a late transcriptional response from the GFAT promoter, as indicated by Northern blotting and nuclear run-on experiments (13) . To determine if the GFAT promoter can confer an EGF response, various proximal segments of the promoter were transfected into MDA468 cells. The cells were treated for 18 h with 5 nM EGF prior to assay of reporter function. Table 1 indicates that the promoter, even when 5′-deleted to -36, was still capable of confering the EGF response to the luciferase reporter. When deleted to -7, no promoter activity could be detected. Since all of the tested deletion constructs contained at least one Sp1 binding site, it is possible that the EGF response might be confered by this element.
DISCUSSION
GFAT appears to be the unique enzyme that allows de novo synthesis of glucosamine from glucose (1, 8) . Glucosamine can then be utilized in the synthesis of other hexosamines and these hexosamines are vital for post-translational modification of proteins by glycosylation. Thus, the rate of glucosamine synthesis must be coupled to the rate of glycoprotein synthesis. In addition, glucose metabolism to glucosamine appears to play a role in other metabolic pathways, including glucose-induced insulin desensitization in adipocytes (3), glycogen synthase activity (4), pyruvate kinase activity (5) and glucose-induced growth factor expression in vascular smooth muscle cells (6) (7) (8) . These metabolic consequences of glucosamine require that the synthesis of this sugar be under strict control. The major known points of control appear to be as follows: first, the concentration of the GFAT substrate, fructose-6-phosphate, is highly regulated at the level of its glycolytic metabolism to fructose 1,6-bisphosphate (28, 29) ; second, GFAT activity is regulated allosterically by its downstream product, UDP-GlcNAc (9,10); third, GFAT activity can be influenced by the quantity of GFAT protein in the cell (7, 8, 11) . The amount of GFAT protein in the cell reflects the balance between synthesis and degradation. While little is known about the half-life of the GFAT protein, our prior studies have shown that transcription of the GFAT gene appears to be coupled to the cell cycle and can also be regulated by glucose and glucosamine (13) . To further characterize the transcriptional regulation of GFAT, we cloned the 5′-flanking region of the GFAT gene.
These studies show that the 5′-flanking region of the GFAT gene contains the promoter. This segment of the gene directs transcriptional initiation of a luciferase reporter gene from a tight cluster of nucleotides (-4 to +3) including and surrounding the transcriptional initiation site observed in the native GFAT gene.
We attribute this imprecise initiation to the lack of a TATA box. Furthermore, restriction analysis of DNA from the four independently cloned λ phages containing the GFAT gene yielded fragment sizes that matched those observed on Southern blots of mouse genomic DNA cut with the same restriction enzymes. These observations suggest that the GFAT gene is a single copy gene in the mouse genome and that the cloned gene did not contain a rearrangement. MDA468 cells were transfected with GFAT-luciferase reporter constructs containing the indicated region of the GFAT promoter. The cells were co-transfected with the CMV-β-galactosidase construct to control for transfection efficiency. Eighteen hours following transfection, the cells were placed in serum-free medium for 24 h, then stimulated with or without 5 nM EGF for 18 h prior to luciferase assay. The same extracts were assayed for β-galactosidase activity and the luciferase activity, expressed in thousands of RLU, was corrected for variations in β-galactosidase. Shown are the normalized luciferase activities in thousands of RLU. Background activity was ∼100 RLU. NA indicates that the ratio is non-applicable because the reporter activity was not significantly above background. The transfections were performed in triplicate and variations were <8% of the mean.
Deletional analysis of the GFAT promoter indicated that most of the transcriptional activity resided between bases -275 and +19 relative to the transcription start site. The sequence distal to -470 appeared to repress promoter activity slightly and the basal promoter appeared to reside between -120 and +19. The region between -120 and -275 enhanced activity almost 6-fold above basal, suggesting that this region contains important elements that contribute to activity of the GFAT gene. The identity of these elements remain to be determined. This paper describes a detailed analysis of this proximal segment of the GFAT promoter between -120 and +19.
DNase I footprinting analysis of the proximal GFAT promoter indicated that recombinant Sp1 binds to three sites in this segment of the GFAT gene. Gel shift analysis confirmed that native Sp1 in nuclear extracts also specifically bound these sites, whereas binding of other transcription factors to these sites was not detectable. Mutagenesis at these Sp1 binding sites markedly reduced promoter function, whereas mutations at two other sites had no significant effect on function of the promoter. Taken together, these studies indicate that transcription from the proximal GFAT promoter is principally under control of the transcription factor Sp1. Sp1 is a ubiquitous transcription factor that appears to be involved in the transcription of many viral and mammalian genes. Sp1 is modified post-translationally both by phosphorylation (30) and glycosylation with O-GlcNAc (31) . The role of these modifications has not been determined, although the major phosphorylation appears to require binding of Sp1 to DNA (30) and the glycosylation may be involved in transcriptional activation but not DNA binding by Sp1 (31) . Sp1 has been considered to confer constitutive expression of housekeeping genes. However, transcription of several genes considered to be housekeeping genes has been shown to be regulated under certain circumstances. For example, those genes encoding enzymes required for DNA synthesis are regulated in a cell cycle-dependent manner (see for example 32). The dihydrofolate reductase gene has been shown to be regulated in a manner that depends on the transcriptional activity of the transcription factor E2F, which in turn is regulated by retinoblastoma (Rb) protein (33) (34) (35) (36) (37) . Rb phosphorylation is regulated in a cell cycle-dependent manner and the phosphorylation state of Rb controls its ability to bind and neutralize E2F transcriptional activity. At the G1/S boundary, Rb becomes hyperphosphorylated and thereby incapable of binding E2F. E2F is then liberated to activate its target genes. Recently it has been proposed, but not proven, that Sp1 activity may also be indirectly controlled by Rb. An inhibitor of Sp1 (Sp1-I) has been described that blocks the ability of Sp1 to bind to DNA (38) . Sp1-I also appears to be bound by Rb, raising the possibility that Rb might control Sp1 activity through sequestration of Sp1-I. Sp1 activity has also been shown to be regulated in response to DNA methylation (23) during the differentiation of a leukemic cell line in response to phorbol esters (26) and cell cycle regulation of gene expression has been attributed in part to Sp1 (35) . Since GFAT activity is required for post-translational modification of proteins and protein synthesis varies with the growth state of cells, transcriptional regulation of GFAT may contribute to the control of GFAT activity under various growth conditions. Indeed, activation of GFAT gene transcription appears to be a late response to EGF stimulation (13) .
The GFAT promoter conferred a response to EGF in transfection studies. This response was seen even after normalization to the activity of β-galactosidase, whose expression was under the control of the co-transfected CMV-βGal plasmid. The CMV construct has been shown to be non-responsive to EGF in MDA468 cells (7) . While more distal elements in the GFAT promoter may have contributed to the EGF response, the proximal 120 bp of the promoter also displayed EGF responsiveness. Deletional analysis of this 120 bp segment of the promoter indicated that even the most proximal 36 bp of the promoter exhibited the EGF response. This segment of the promoter contains one of the three Sp1 binding sites characterized in the 120 bp segment of the gene. While it is tempting to attribute the EGF response to these Sp1 binding sites, it is not possible to do so definitively, because removal of all the Sp1 binding sites results in a totally inactive promoter. The lack of a response from an otherwise inactive promoter cannot be interpreted as resulting from removal of the EGF response element. In the presence of the one Sp1 binding site in the -36 promoter, it remains possible that the EGF response resulted from a cryptic enhancer element present elsewhere in the plasmid (39) . Whether the proximal GFAT promoter and Sp1 that binds to this segment of the gene are responsible for this transcriptional response to EGF or other stimuli remains to be elucidated by direct studies on Sp1 protein and inducible modifications of this protein. Such studies are underway in this laboratory.
